Meanwhile, we observed that pathways associated with the response of anti-PD-L1 agent atezolizumab, such as cytokine-cytokine receptor interaction, homologous recombination, MicroRNAs in cancer, RNA degradation, and IFN-γ signature, were significantly enriched in PDAC samples with high IL2RA expression (Fig. 7C). The gene discussed is IL2RA; the disease is cancer.